Opioid Addiction Treatment Options: Medications, Therapy, and Rehab

Opioid use disorder (OUD) is a chronic, relapsing medical condition regulated under federal statutes including the Controlled Substances Act (21 U.S.C. § 801 et seq.) and overseen by agencies including the Substance Abuse and Mental Health Services Administration (SAMHSA) and the Drug Enforcement Administration (DEA). Treatment spans three primary modalities: FDA-approved medications, evidence-based behavioral therapies, and structured rehabilitation settings ranging from inpatient medical units to community-based outpatient programs. This page maps the clinical components, regulatory classifications, and structural tradeoffs that define the current treatment landscape for opioid addiction in the United States.

• Definition and Scope
• Core Mechanics or Structure
• Causal Relationships or Drivers
• Classification Boundaries
• Tradeoffs and Tensions
• Common Misconceptions
• Checklist or Steps
• Reference Table or Matrix

Definition and Scope

Opioid use disorder is formally defined under the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as a problematic pattern of opioid use leading to clinically significant impairment or distress, with at least 2 of 11 specified criteria present within a 12-month period (American Psychiatric Association, DSM-5). The disorder spans mild (2–3 criteria), moderate (4–5 criteria), and severe (6 or more criteria) presentations.

Federal regulatory scope is substantial. SAMHSA maintains authority over Opioid Treatment Programs (OTPs) under 42 CFR Part 8, which governs methadone dispensing for OUD. The DEA schedules the three primary pharmacotherapies — methadone (Schedule II), buprenorphine (Schedule III), and naltrexone (not scheduled, non-controlled) — under 21 CFR Part 1308. The opioid treatment program regulations framework governs facility certification, staffing ratios, and dispensing protocols at the federal level, with state agencies adding an additional licensing layer.

Scope by scale: the CDC reported approximately 80,411 opioid-involved overdose deaths in the United States in 2021 (CDC, Drug Overdose Surveillance), establishing OUD treatment as a public health priority of the first order. SAMHSA's 2022 National Survey on Drug Use and Health (NSDUH) estimated that approximately 6.1 million people aged 12 or older had OUD in the prior year (SAMHSA NSDUH 2022).

Core Mechanics or Structure

Opioid addiction treatment operates across three interlocking domains: pharmacotherapy, behavioral intervention, and level-of-care placement.

Pharmacotherapy targets the neurobiological substrate of OUD. Three medications hold FDA approval for OUD specifically:

1. Methadone — a full mu-opioid agonist administered daily at federally certified OTPs. Effective dose ranges typically fall between 60 and 120 mg/day, though individualized titration applies (SAMHSA TIP 43). Its long half-life (24–36 hours) stabilizes receptor activity and suppresses withdrawal.

2. Buprenorphine — a partial mu-opioid agonist with a ceiling effect on respiratory depression, commonly combined with naloxone in the formulation marketed as Suboxone. Under the SUPPORT Act of 2018 (P.L. 115-271) and subsequent regulatory changes finalized in 2023, DEA-registered practitioners can prescribe buprenorphine for OUD without a separate DATA waiver, broadening prescriber access. The buprenorphine/Suboxone treatment page covers prescribing pathway details.

3. Naltrexone — a full opioid antagonist available as a daily oral tablet or as extended-release injectable naltrexone (Vivitrol, 380 mg IM monthly). Because naltrexone carries no abuse potential, it is unscheduled and faces no DEA prescribing restrictions. The naltrexone/Vivitrol treatment page covers administration protocols and contraindications.

Behavioral therapies address cognitive, emotional, and social dimensions of OUD. Modalities with the strongest evidence base in NIDA's published literature include Cognitive Behavioral Therapy (CBT), Contingency Management (CM), and Motivational Enhancement Therapy (MET). The behavioral therapies in rehab page provides modality-specific detail.

Level-of-care placement follows the ASAM (American Society of Addiction Medicine) Patient Placement Criteria, which defines six dimensions of assessment and five broad levels of care — from Level 0.5 (early intervention) through Level 4 (medically managed intensive inpatient). See levels of care: ASAM criteria for the full dimensional framework.

Causal Relationships or Drivers

OUD develops through a convergence of neurobiological, genetic, psychological, and social factors. Chronic opioid exposure downregulates endogenous opioid receptor density and disrupts dopaminergic reward circuitry in the nucleus accumbens and prefrontal cortex, creating physiological dependence and compulsive drug-seeking behavior — mechanisms documented extensively in NIDA's foundational research publications (NIDA, Drugs, Brains, and Behavior: The Science of Addiction).

Genetic heritability for OUD is estimated at approximately 40–60% based on twin study data published in research-based literature synthesized by NIDA. Co-occurring psychiatric conditions — including major depressive disorder, PTSD, and anxiety disorders — amplify risk of both initiation and relapse. The relationship between co-occurring disorders and dual diagnosis treatment is a primary clinical driver of care complexity.

Social determinants — including housing instability, justice system involvement, and limited access to primary care — influence both treatment entry and retention. SAMHSA's continuum-of-care model explicitly incorporates social determinants as treatment targets, not merely background variables.

Classification Boundaries

Opioid addiction treatment options divide along four primary classification axes:

By medication class:
- Agonist therapies (methadone, buprenorphine) maintain receptor activity to prevent withdrawal and craving
- Antagonist therapies (naltrexone) block opioid receptors without activating them
- No approved partial antagonist formulation exists for OUD outside the buprenorphine/naloxone combination

By regulatory setting:
- OTP (Opioid Treatment Program): federally certified under 42 CFR Part 8; the only setting legally authorized to dispense methadone for OUD on an outpatient basis
- Office-Based Opioid Treatment (OBOT): DEA-registered physician or advanced practice clinician prescribing buprenorphine; may operate in primary care, psychiatry, or addiction medicine settings
- Hospital/inpatient settings: may administer all three medications; methadone for pain management (not OUD) can be prescribed in general medical settings

By care level:
- Detox services in drug rehab represent Level 3.7 or 4-WM (medically managed withdrawal management) under ASAM criteria
- Inpatient rehab medical services operate at ASAM Level 3.7 or Level 4
- Outpatient rehab medical services span ASAM Levels 1 and 2
- Intensive outpatient programs and partial hospitalization programs occupy Levels 2.1 and 2.5 respectively

By therapy orientation:
- Structured 12-step facilitation (see 12-step programs in rehab)
- Non-12-step modalities (see non-12-step rehab programs)
- Trauma-informed approaches (see trauma-informed care in rehab)

Tradeoffs and Tensions

Medication stigma versus efficacy evidence: Methadone and buprenorphine carry robust efficacy evidence for reducing illicit opioid use, overdose mortality, and HIV transmission risk, yet both face persistent stigma within abstinence-only treatment philosophies. SAMHSA's Treatment Improvement Protocol 63 directly addresses this tension, affirming that MAT "is not trading one addiction for another" (SAMHSA TIP 63).

Access versus regulatory restriction: OTP regulations under 42 CFR Part 8 historically required daily in-person methadone dispensing. COVID-19 emergency waivers permitted take-home doses for up to 28 days; SAMHSA's 2024 final rule (89 FR 1263) made flexibilities for take-home methadone permanent under defined criteria, representing a structural shift in access policy.

Short-term versus long-term treatment duration: Clinical guidance from ASAM and SAMHSA supports extended maintenance pharmacotherapy, yet insurance authorization structures frequently impose 30-day or 90-day limits that conflict with chronic disease management models. The drug rehab length of stay page documents payer-specific duration standards.

Integrated versus siloed care: OUD commonly co-occurs with chronic pain, hepatitis C, and psychiatric disorders. Treatment programs that address OUD in isolation from these conditions produce weaker outcomes, yet integrated care models require cross-specialty coordination that many facilities lack the staffing to sustain.

Common Misconceptions

Misconception: Medication-Assisted Treatment (MAT) is only for severe cases.
Correction: ASAM criteria apply MAT recommendations across mild, moderate, and severe OUD presentations. The severity specifier governs dosing and level-of-care placement, not eligibility for pharmacotherapy.

Misconception: Naltrexone works the same way as methadone or buprenorphine.
Correction: Naltrexone is a full antagonist with zero agonist activity. It neither prevents withdrawal (patients must be fully detoxified before initiation) nor produces any opioid effect. Methadone and buprenorphine are agonists or partial agonists that actively suppress withdrawal by occupying opioid receptors.

Misconception: Completing a 28-day residential program constitutes treatment completion.
Correction: NIDA's Principles of Drug Addiction Treatment (4th edition) states that treatment durations of fewer than 90 days are of limited effectiveness for most patients. OUD is classified as a chronic condition; the 28-day standard reflects insurance authorization history, not clinical consensus.

Misconception: Buprenorphine requires a specialized DEA waiver that most doctors cannot obtain.
Correction: The DEA Omnibus Rule of 2023, implementing provisions of the SUPPORT Act, eliminated the separate DATA 2000 waiver requirement. Any DEA-registered practitioner with Schedule III prescribing authority may now prescribe buprenorphine for OUD within their scope of practice.

Misconception: Therapy alone is sufficient for opioid use disorder.
Correction: For opioid use disorder specifically, SAMHSA, NIDA, and ASAM all identify pharmacotherapy combined with behavioral treatment as the standard of care. Behavioral therapy alone shows substantially higher relapse rates for OUD compared to combined treatment, based on meta-analyses cited in NIDA's research synthesis publications.

Checklist or Steps

The following sequence reflects the standard clinical pathway for OUD treatment entry as documented in SAMHSA's Treatment Improvement Protocol series. This is a structural reference, not a clinical protocol.

Phase 1 — Assessment and Diagnosis
- [ ] Structured diagnostic interview using DSM-5 criteria to confirm OUD and severity level
- [ ] Medical history review including current medications, hepatic function, cardiac history (relevant to methadone QTc risk), and pregnancy status
- [ ] Toxicology screening to identify polysubstance use patterns
- [ ] Mental health screening for co-occurring disorders (PHQ-9, GAD-7, PC-PTSD-5 or equivalent validated instruments)
- [ ] ASAM six-dimensional assessment to determine level-of-care placement

Phase 2 — Stabilization
- [ ] Selection of pharmacotherapy based on patient history, preference, co-occurring conditions, and access to OTP versus OBOT settings
- [ ] Medically supervised withdrawal management if clinically indicated prior to naltrexone induction
- [ ] Dose titration to therapeutic range with monitoring for adverse effects
- [ ] Initiation of behavioral therapy concurrent with or immediately following medication stabilization

Phase 3 — Active Treatment
- [ ] Regular urine drug screening per program protocol
- [ ] Individual and/or group counseling sessions at frequency consistent with ASAM level of care
- [ ] Coordination with primary care for management of co-occurring medical conditions
- [ ] Housing, legal, and vocational needs assessment through case management

Phase 4 — Continuing Care and Relapse Prevention
- [ ] Transition planning to lower level of care per ASAM criteria
- [ ] Relapse prevention planning with documented high-risk situations and coping strategies
- [ ] Naloxone prescribing and training for patient and household members
- [ ] Linkage to peer recovery support, sober living, or community mutual-aid programs
- [ ] Scheduled follow-up at 30, 60, and 90 days post-discharge

Reference Table or Matrix

References

• SAMHSA — Substance Abuse and Mental Health Services Administration
• [SAMHSA TIP 43: Medication-Assisted Treatment for O